Overview

• Lecanemab shown to slow cognitive decline by 27% in early-stage Alzheimer's patients.
• NICE cites high costs and modest benefits in decision against NHS coverage.
• The drug requires intensive monitoring and bi-weekly infusions, adding to the expense.
• Approximately 70,000 patients in England would have been eligible for treatment.
• Alzheimer's charities urge government intervention to ensure equitable access.